Hydroxychloroquine intranasal - APT Pharmaceuticals
Alternative Names: APT-004; APT-005; APT-006Latest Information Update: 23 Dec 2021
At a glance
- Originator APT Pharmaceuticals Inc
- Class Antimalarials; Antivirals; Chlorobenzenes; Disease-modifying antirheumatics; Ethanolamines; Quinolines; Small molecules
- Mechanism of Action Phospholipase A2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Nasal polyps; Rhinovirus infections; Seasonal allergic rhinitis
Most Recent Events
- 31 Jul 2013 No development reported - Preclinical for Nasal polyps in USA (Intranasal)
- 31 Jul 2013 No development reported - Preclinical for Rhinovirus infections in USA (Intranasal)
- 31 Jul 2013 No development reported - Preclinical for Seasonal allergic rhinitis in USA (Intranasal)